Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Announces New Employee Inducement Grant
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Announces New Employee Inducement Grant
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Tickers AERI
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.